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Abstract 18 
O
6
meG is one of the most pre-mutagenic, pre-carcinogenic and pre-cytotoxic DNA 19 
lesion formed by alkylating agents. Repair of this DNA damage is achieved by the 20 
protein MGMT, which transfers the alkyl groups from the O
6
position of guanine to a 21 
cysteine residue in the active centre of MGMT. Since O
6
meG repair by MGMT, is a 22 
stoichiometric reaction that irreversibly inactivates MGMT, which is subsequently 23 
degraded, the repair capacity of O
6
meG lesions is dependent on existing MGMT active 24 
molecules. In the absence of active MGMT, O
6
meG is not repaired and during 25 
replication, O
6
meG:T mispairs are formed. MMR system recognizes these mispairs and 26 
introduces a gap into the strand. If O
6
meG remains in one of the template strands the 27 
futile MMR repair process will be repeated, generating more SB.The toxicity of O
6
meG 28 
is, therefore, dependent on MMR and DNA SB induction of cell death. MGMT, on the 29 
other hand, protects against O
6
meG toxicity by removing the methyl residue from the 30 
guanine. While removal of O
6
meG makes MGMT an important anticarcinogenic 31 
mechanism of DNA repair its activity significantly decreases the efficacy of cancer 32 
chemotherapeutic drugs that aim at achieving cell death through the action of the MMR 33 
system on unrepaired O
6
meG lesions. 34 
Here, we report on a modification of the comet assay (CoMeth) that allows the 35 
qualitative assessment of O
6
meG lesions after their conversion to strand breaks in 36 
proliferating MMR proficient cells after MGMT inhibition. This functional assay allows 37 
the testing of compounds with effects on O
6
meG levels, as well as on MGMT or MMR 38 
activity in a proliferating cell system. The expression of MGMT and MMR genes is 39 
often altered by promoter methylation and new epigenetically active compounds are 40 
being designed to increase chemotherapeutic efficacy. The CoMeth assay allows the 41 
testing of compounds with effects on O
6
meG, MGMT or MMR activity. This 42 
proliferating cells system complements other methodologies that look at effects on these 43 
parameters individually through analytical chemistry or in vitro assays with 44 
recombinant proteins.  45 
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54 
1. Introduction 55 
Alkylating agents are ubiquitous. They are present in the environment (e.g. cigarette 56 
smoke and fuel combustion), diet (e.g. presence of nitrosamines in food), or are 57 
endogenously produced [1, 2]. Although generally in low concentrations, alkylating 58 
agents may be mutagenic and carcinogenic [3]. Another source of human exposure to 59 
alkylating agents is cancer chemotherapy [4] where several alkylating agents are used 60 
due to their ability to induce extensive DNA damage and cell death. 61 
Alkylating agents can react with different nucleophilic atoms on the DNA bases, 62 
inducing a large amount of DNA lesions. Of the various types of alkylation damage, N-63 
alkylated adducts, such as N
7
-methylguanine (N
7
meG), N
3
-methyladenine (N
3
meA) and 64 
N
3
-methylguanine (N
3
meG) are the most abundant (more than 80% of alkylated bases).  65 
O-alkylated adducts are less abundant (less than 10% of the total alkylated bases) and 66 
include O
6
-methylguanine (O
6
meG) and O
4
-methylthymine (O
4
meT) [5, 6]. In general, 67 
O-alkylations are highly mutagenic and genotoxic, whereas N-alkylations are cytotoxic, 68 
but less mutagenic[1].  69 
The biological effect of these damages depends on the balance between the DNA repair 70 
ability of the cell and the extent of the damage [7].  The most important DNA repair 71 
systems involved in the repair of alkylating damage are: the O
6
-alkylguanine-DNA-72 
alkyltransferase (MGMT), the DNA mismatch repair (MMR) system, and the base 73 
excision repair (BER) system. The repair of O
6
meG is achieved by the protein MGMT, 74 
which transfers the alkyl groups from the O
6
position of guanine, and to a lesser extent 75 
from the O
4
position of thymine, to a cysteine residue in the active centre of the MGMT 76 
molecule. This reaction irreversibly inactivates MGMT that is ubiquitinated and 77 
degradaded in the proteasome [8]. Since O
6
meG repair by MGMT is a stoichiometric 78 
reaction, the repair capacity of O
6
meG is dependent on the number of existing active 79 
MGMT molecules [4, 9]. In the absence of active MGMT, O
6
meG is not repaired by the 80 
cell and during replication pairs with thymine instead of cytosine resulting in O
6
meG:T 81 
mispairs. In mismatch repair (MMR) proficient cells, the O
6
meG:T mispair is 82 
recognized by the MMR proteins  and the new thymine is removed introducing a gap 83 
into the strand. In the next round of replication another thymine is mispaired with 84 
O
6
meG that will again be removed by MMR. Recognition by MMR creates a gap in 85 
DNA by incision in the new replicated strand. If O
6
meG remains in one of the template 86 
strands the MMR repair process will be repeated, creating a “futile repair loop”. This 87 
loop will eventually result in toxic double-strand breaks leading to chromosomal 88 
aberrations, cell-cycle arrest or apoptosis [4, 6, 10-12]. Failure to repair O
6
meG causes 89 
GC-AT transitions [13]. This lesion results in point mutations that may initiate the 90 
carcinogenic process (Fig. 1) [7, 14]. 91 
MGMT and MMR have contrasting effects on DNA O
6
meG. While MGMT is an 92 
efficient mechanism of repair, MMR in contrast, does not remove the methylated base 93 
but introduces more lesions, such as strand breaks (SB), in a futile attempt to repair the 94 
mismatch that results in induction of cell death. In MMR deficient cells O
6
meG fails to 95 
cause apoptosis. Resistance to cell death induction by alkylating agents can be mediated 96 
by both MGMT and MMR. Active MGMT and loss of the MMR pathway protect 97 
cancer cells against the cell death induced by methylating chemotherapeutic drugs, 98 
while increasing the drug’s mutagenecity [15]. Depletion of MGMT activity (for 99 
example, by O
6
-benzylguanine (BG) or by epigenetic silencing of the MGMT gene) 100 
with an intact MMR system results, on the other hand, in reversion of resistance with 101 
high sensitivity to the cytotoxic effects of alkylating drugs [12, 16, 17]. MGMT 102 
inhibitors are frequently used in combination with alkylating drugs to increase 103 
therapeutic efficacy of alkylating agents in tumors that express MGMT [18]. In contrast 104 
with responsiveness to chemotherapeutic agents, an increase in MGMT produced for 105 
instance by dietary constituents may have a beneficial cancer preventive effect [19].  106 
N-methyl-N-nitrosourea (MNU) is an SN1-type alkylating agent that induces O
6
meG 107 
lesions. Repair of these lesions by MGMT provides protection against MNU toxicity 108 
[20]. Depletion of MGMT by BG, a specific inhibitor that acts as a pseudosubstrate, 109 
potentiates the toxicity of this alkylating agent in MMR proficient backgrounds 110 
increasing treatment efficacy [21]. Methyl methanesulfonate (MMS) is another 111 
alkylating agent but of the SN2-type that mainly alkylates nitrogens. In this case, 112 
O
6
meG generated corresponds only to around 0.3% of the total alkylating damages [5]. 113 
The repair reaction of O
6
meG by MGMT leads to stoichiometric (1:1) inactivation of 114 
MGMT. Therefore the number of inactivated MGMT molecules corresponds to the 115 
number of O
6
meG lesions repaired. Currently, O
6
meG levels are measured by [
3
H]-116 
based O
6
-alkylguanine-DNA alkyltransferase inactivation assay or by HPLC [22, 23]. 117 
Christmann and collaborators [24], in a recent review, describe and compare different 118 
methods to detect MGMT: MGMT activity, MGMT promoter methylation and MGMT 119 
protein by immunohistochemistry. Simple, less toxic, and cheaper methods need to be 120 
developed for measurement of O
6
meG levels and evaluation of possible effects of 121 
chemotherapeutic drugs and/or chemopreventive agents on MGMT activity that also 122 
allow to screen the effects on silencing of MGMT or MMR by promoter methylation.  123 
Single cell gel electrophoresis (SCGE) assay or the comet assay is a simple, fast and 124 
low cost method to assess DNA damage [25, 26]. The comet assay is widely used to 125 
measure oxidatively damaged DNA where it allows the evaluation of effects of 126 
environmental factors and chemoprevention by dietary constituents [27, 28]. Alkylating 127 
DNA damage occurs more frequently than oxidative damage and is also a more relevant 128 
driver of mutagenesis or inducer of cell death in chemotherapy. Beside oxidant agents, 129 
comet assay has been also used to assess strand breaks induced by alkylating agents [29, 130 
30]. However, its application to estimate the levels of O
6
meG bases has not been 131 
explored. In the present study we modified the comet assay in order to enable it to 132 
assess O
6
meG, after its conversion into SB in MGMT inactivated and MMR proficient 133 
cells. We demonstrate that by this O
6
methylation specific variant of the comet assay – 134 
CoMeth assay- O
6
meG levels can be assessed, in proliferating and MMR proficient 135 
cells.  136 
 137 
 2. Materials and methods 138 
2.1. Chemicals 139 
MNU, BG, MMS, methoxyamine (Mx), Dulbecco's Modified Eagle Medium (DMEM), 140 
penicillin/streptomycin and trypsin solution were purchased from Sigma-Aldrich (St. 141 
Louis, MO, USA). Fetal bovine serum (FBS) was purchased from Biochrom KG 142 
(Berlin, Germany). SYBR Gold (nucleic acid gel stain) was from Invitrogen Molecular 143 
probes (Oregon, USA).  Protein quantification kit was purchased from Bio-Rad 144 
Laboratories, Inc., (Hercules, CA). Monoclonal anti-MGMT and anti-actin were 145 
purchased from Sigma-Aldrich. Peroxidase-conjugated goat anti-mouse antibody, and 146 
Immobilon western blotting detection reagents were purchased from Santa Cruz 147 
Biotechnology, Inc. (Santa Cruz, CA) and Millipore (Billerica, MA), respectively. All 148 
other reagents and chemicals used were of analytical grade.  149 
 150 
2.2. Cell culture  151 
Caco-2 cells (derived from human colon carcinoma) and HCT116 cells were maintained 152 
as monolayer cultures in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 153 
with 10% FBS and antibiotics (100U/ml penicillin and 100µg/ml streptomycin), under 154 
an atmosphere of 5% CO2 at 37ºC. Cells were trypsinized when nearly confluent.  155 
Stock solutions of MNU were prepared in dimethyl sulphoxide (DMSO), while BG and 156 
MMS were prepared in PBS and aliquots kept at -20ºC. The final concentration of 157 
DMSO in medium was <0.5%. The controls received DMSO or PBS according to the 158 
compound in study.  159 
Cells were seeded onto 6-well plates (western blot) or 12-well plates (TUNEL and 160 
comet assay) with 2 or 1 ml/well, respectively, at a density of 0.1 × 10
6
 cells/ml. 161 
Twenty-four hours after plating, the medium was discarded and fresh medium 162 
containing BG (100μM) to inhibit MGMT was added. Two hours later, MNU (500μM) 163 
was added to induce alkylating damages, without changing the medium. Cells were also 164 
treated only with BG, MNU or DMSO as controls. For each assay, cells were collected 165 
after specific times of incubation as described below.  166 
 167 
2.3. Apoptosis assay  168 
The effect of BG and/or MNU treatment on induction of apoptosis in Caco-2 and 169 
HCT116 cells was assessed by TUNEL assay. The number of apoptotic cells was 170 
counted after 48, 72 and 96h of MNU incubation as previously described [31]. 171 
 172 
2.4. MGMT protein expression 173 
MGMT expression in Caco-2 cells was monitored by western blotting after 24, 48 and 174 
72h of MNU incubation (with or without BG treatment). The effect of different 175 
concentrations of BG on MGMT protein expression was also measured in Caco-2 cells 176 
after 72h of incubation.  177 
Protein concentration was measured with the DC protein assay following the 178 
manufacturer’s instructions and 20µg/well were separated on 12% SDS-PAGE and 179 
transferred to PVDF membranes. Membranes were blocked and incubated with the 180 
monoclonal anti-MGMT antibody (1:4,000 dilution) overnight, and then incubated with 181 
the secondary antibody for 1 h at room temperature. Imunoreactive bands were acquired 182 
using the Chemidoc camera (BioRad) and band area intensity quantified by Quantity 183 
One software (BioRad). The results were expressed as percentage of control (cells 184 
without any treatment). 185 
 186 
2.5. Assessment of O
6
meG levels by the comet assay in MMR efficient cells 187 
To verify if the comet assay can be applied to assess the O
6
meG levels in single cells 188 
and to estimate MGMT activity, two colon cell lines were used: Caco-2 cells as MMR 189 
efficient cells and HCT116 cells as a MMR deficient cell line. 190 
After 24, 48 and 72h of incubation of Caco-2 or HCT116 cells with MNU (with or 191 
without BG) DNA damage was assessed by the comet assay as previously described 192 
[28, 32]. Briefly, after treatment, Caco-2 and HCT116 cells were trypsinized, washed, 193 
centrifuged, and the pellet suspended in low melting point agarose; about 2x10
4 
cells 194 
were placed on a slide (pre-coated with 1% normal melting point agarose and dried) and 195 
covered with a coverslip. After 10 min at 4 ºC, the coverslips were removed and slides 196 
were placed in lysis solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris Base, pH 197 
10 plus 1% Triton X-100) for 1h at 4ºC. Slides were then placed in a horizontal 198 
electrophoresis chamber with electrophoresis solution (300 mM NaOH, 1 mM 199 
Na2EDTA, pH >13) for 40 min at 4ºC for the DNA to unwind before electrophoresis 200 
was run for 20 min at 0,8V/cm and ~300 mA. After electrophoresis, slides were washed 201 
two times with PBS and dried at room temperature. For analysis of the comet images, 202 
slides were stained with SYBR Gold solution for 30 min at 4ºC; after drying, slides 203 
were analyzed in a fluorescence microscope and Comet IV analysis system (Perceptive 204 
Instruments Ltd, Haverhill, UK) was used to calculate the parameter % of DNA in tail. 205 
About 100 randomly selected cells were analyzed per sample. 206 
 207 
2.5.1. Effect of BG on O
6
meG levels in Caco-2 cells assessed by the comet assay 208 
To assess the effect of BG on O
6
meG levels, Caco-2 cells were treated with different 209 
concentrations of BG (0-100μM), followed by the addition of 500μM MNU two hours 210 
later (controls received vehicle only) without medium change. After 72h of MNU 211 
incubation DNA damage was assessed by the comet assay as above. 212 
 213 
2.5.2. Assessment of MMS-induced O
6
meG levels by the comet assay in MMR- 214 
proficient cells 215 
To assess the ability of our system to assess O
6
meG levels by comet assay induced by 216 
different alkylating agents, Caco-2 cells were incubated with different concentrations of 217 
BG before treatment with MMS (200 µM). DNA damage was assessed 1and 72h after 218 
MMS treatment. 219 
 220 
2.6. Statistical analysis 221 
Results were expressed as mean ± SEM from at least 4 independent experiments. 222 
Significant differences (P<0.05) were evaluated by ANOVA or Student’s t-test, as 223 
appropriate.  224 
 225 
3. Results 226 
3.1. Assessment of MNU-induced O
6
meG levels by the comet assay in MMR efficient 227 
cells 228 
We hypothesized that the comet assay can be used to assess the levels of O
6
meG in 229 
DNA induced by alkylating agents, such as MNU, in MMR proficient cells. Unrepaired 230 
O
6
meG damage, due to the inactivation of MGMT in the presence of BG, would be 231 
recognized by the MMR pathway, in MMR-proficient cells, upon cell replication. In 232 
this process, the MMR system introduces a SB at sites of damage that can be recognized 233 
by the comet assay and % DNA in tails will be higher as the extent of MGMT inhibition 234 
increases. 235 
To test this hypothesis, Caco-2 cells – MMR-proficient – were treated with the 236 
alkylating agent MNU in the presence or absence of the MGMT inhibitor BG. DNA 237 
damage was assessed by the comet assay at different incubation times with MNU. As 238 
shown in Fig. 2, after one hour of incubation with MNU, significant DNA damage was 239 
detected with and without the presence of BG. DNA damage decreased with increasing 240 
time, which corresponds to the repair of the initial DNA damage (such as SB, AP sites) 241 
induced by MNU. After 72hr, the levels of DNA damage reached control values of cells 242 
without MNU or BG treatment. However, in Caco-2 cells in the presence of BG, DNA 243 
damage detectable by the comet assay was still significant and it even increased slightly 244 
when compared with 48h of treatment. Cells pretreated with BG but without MNU 245 
incubation did not show any increase of DNA damage during the entire period of 246 
treatment. 247 
 248 
3.2. Cytotoxicity of MNU and BG 249 
The potential cytotoxicity of MNU and BG were evaluated in Caco-2 during the 250 
incubation period. By morphologic observations, none of the treatments resulted in cell 251 
death until the 72h of incubation (data not shown). Induction of cell death by apoptosis 252 
was also evaluated by the TUNEL assay. As shown in Fig. 3, both MNU (500µM) and 253 
BG (100µM), alone or in combination, did not increase the number of apoptotic cells in 254 
Caco-2 until 72h of incubation. However, when Caco-2 cells were pretreated with BG 255 
followed by MNU treatment the number of apoptotic cells increased significantly at 256 
96h. This effect is in agreement with the DNA damage observed at 72h when cells were 257 
co-incubated with BG and MNU, due to the recognition of unrepaired O
6
meG base 258 
damage by the MMR system, introduction of SB that lead to cell death. 259 
 260 
3.3. MGMT protein expression 261 
The repair reaction of MGMT is stoichiometric and leads to autoinactivation, and BG is 262 
a pseudosubtrate for MGMT, that acts as an inhibitor of this enzyme by inducing its 263 
autoinactivation and consequent degradation by the proteasome [33]. The extension of 264 
MGMT inhibition is, therefore, reflected in the decreased expression levels of the 265 
protein. 266 
The expression levels of MGMT were evaluated after treatment of Caco-2 cells with 267 
different concentrations of BG (0.05-100 µM) for 72h of incubation. As shown in Fig. 268 
4, MGMT protein levels decreased with increasing concentrations of BG. Cells treated 269 
with 0.5 µM BG showed a decrease of around 50% in MGMT protein levels, while in 270 
cells treated with 100 µM of BG only around 5% of the control MGMT levels were 271 
present.  272 
To test if MGMT was still inactivated by BG after 72h of incubation under the 273 
experimental conditions used for comet assay, the levels of this protein were evaluated 274 
by western blot. As shown in Fig. 5, BG (100 µM) was able to significantly decrease the 275 
levels of MGMT during the entire experimental period, independently of the presence 276 
of MNU. When Caco-2 cells were incubated with MNU alone, a slight decrease was 277 
observed in MGMT protein expression likely due to MGMT being used to repair 278 
O
6
meG induced by MNU. 279 
 280 
3.4. Concentration-dependent effect of BG on MNU-induced O
6
meG levels in Caco-2 281 
cells assessed by the comet assay 282 
To test if the concentration-dependent effect of BG on MGMT protein levels correlated 283 
with the accumulation of O
6
meG induced by MNU measured by the comet assay, Caco-284 
2 cells were incubated with different concentrations of BG (0-100μM) before MNU 285 
addition, and DNA damage was measured after 72h. Again, one hour after incubation 286 
with MNU DNA damage increased in comparison with the control (cells without 287 
MNU), but was completely repaired after 72h of incubation in cells without pre-288 
treatment with BG (Fig. 6). When Caco-2 cells were pre-treated with different 289 
concentrations of BG followed by exposure to MNU, a concentration-dependent 290 
increase in DNA damage at 72h was observed, which was significant for 100μM BG 291 
(Fig. 6). This means that the concentration of 100μM was enough to totally inactivate 292 
cellular MGMT in Caco-2 and the unrepaired O
6
meG lesions converted by MMR in SB 293 
were detectable by the comet assay. 294 
 295 
3.5. Assessment of MNU-induced O
6
meG levels by the comet assay in MMR-deficient 296 
cells 297 
To prove the involvement of MMR system in the recognition of O
6
meG and consequent 298 
introduction of SB that are detectable by comet assay, HCT116, a MMR deficient colon 299 
cell line, was used. As in Caco-2, after one hour of incubation with MNU initial DNA 300 
damages were detected in HCT116 and 72hr after they were totally repaired (fig 7a). 301 
However, no differences were observed between cells with and without BG treatment 302 
after 72hr of MNU incubation. In MMR deficient cells therefore, inhibition of MGMT 303 
does not increase SB. 304 
In the TUNEL assay (fig 7b), both MNU (500µM) and BG (100µM), alone or in 305 
combination, did not increase the number of apoptotic cells in HCT116 cells. 306 
 307 
3.6. Assessment of the effects of MMS by the comet assay in MMR-proficient cells 308 
To test if our system is specific for O
6
meG, MMS, an alkylating agent that does not 309 
induce O
6
meG lesions in significant amounts was used. Caco-2 cells were treated with 310 
MMS in the presence or absence of the BG. DNA damage was assessed by the comet 311 
assay after different times of incubation with MMS such as in MNU treatment. As 312 
shown in Fig. 8, one hour after incubation with MMS, significant DNA damage was 313 
detected in Caco-2 cells.  After 72hr of incubation, the levels of DNA damage decreased 314 
until control values without MMS treatment were reached. In the presence of BG, DNA 315 
damage repair was similar to control because MMS induces very low levels of O
6
meG 316 
(almost nonexistent). Due to the absence of O
6
meG induction by MMS, the damages are 317 
not converted to SB by MMR and therefore nothing is detected by the comet assay.  318 
 319 
4. Discussion 320 
Here we report that the comet assay can be used to assess the levels of a specific 321 
alkylating DNA damage, O
6
meG, due to the fact that these lesions are converted to SB 322 
by proliferating, MMR proficient cells when MGMT is inhibited. Caco-2 cells were 323 
treated with MNU and significant DNA damage (such as SB and AP sites) was 324 
observed by the comet assay after 1h of incubation. Most of the damage was totally 325 
repaired at the time of the second round of replication in Caco-2 cells. However, when 326 
Caco-2 cells were also incubated with BG, the inhibitor of MGMT, significantly higher 327 
DNA damage was present at 72h. MGMT is a suicide repair enzyme responsible for 328 
O
6
meG repair. If the enzyme does not repair all O
6
meG lesions, O
6
meG:T mismatches 329 
will be generated upon cell division. This new damage is recognized by the proteins of 330 
the MMR pathway that, in attempting to repair the mismatch, generate SB in the DNA. 331 
As long as O
6
meG remains in one of the DNA template strands, the MMR repair 332 
process will be repeated, creating a “futile repair loop” that results in double-strand 333 
breaks. Accumulation of SB will eventually induce cell death by apoptosis.   334 
In this study, BG was used at a concentration that inhibited MGMT in Caco-2 cells, as 335 
shown by western blot. When the concentration of BG was decreased, the expression of 336 
MGMT at 72h was higher in a BG concentration-dependent manner. This effect was 337 
reflected in the comet assay results, where increasing concentrations of BG resulted in 338 
increasing DNA damage at 72h, showing that detected SB in the presence of BG result 339 
from unrepaired O
6
meG base damages due to inhibition of MGMT. 340 
In agreement with this, in Caco-2 cells co-treated with BG and MNU the number of 341 
apoptotic cells increased after 96h of incubation. This is due to the accumulation of SB 342 
introduced by the action of the MMR system on O
6
-meG:T mismatch (since O
6
meG 343 
still remains in the DNA template). SB accumulate and become cytotoxic after some 344 
replication rounds inducing cell death by apoptosis. Treatment with MNU or BG alone 345 
did not induce apoptosis, since in the first case O
6
meG is repaired by MGMT and in the 346 
second, in spite of the almost total inhibition of MGMT, the basal levels of O
6
meG are 347 
negligible and not enough to produce SB and induce apoptosis.  348 
In order to test the specificity of this modified comet to detect SB originated by MMR 349 
action on O
6
meG, a MMR deficient cell line (HCT116) was used. As expected, in 350 
HCT116 cells, DNA damage remains similar to basal levels even in the presence of BG. 351 
In MMR deficient cells the comet assay will not detect O
6
meG damages because they 352 
will not be transformed into SB and therefore will be undetectable by the comet assay. 353 
In accordance with the comet assay results, in the MMR deficient HCT116 cells, 354 
apoptosis did not occur with co-treatment with MNU and BG, since O
6
-meG:T 355 
mismatches are not recognized in these cells, SB are not produced and therefore no 356 
apoptosis takes place.  357 
As referred previously, MNU also induces N-alkylation lesions that are repaired by 358 
BER pathway. The N-methylpurine-DNA glycosylase (MPG), a glycosylase of BER 359 
pathway, initiate N-alkylation repair by hydrolysis of the N-glycosylic bond creating an 360 
AP site that is repaired by the other enzymes of the BER pathway [5, 34]. To test the 361 
possibility of N-alkylations involvement on the detected SB in the presence of BG, 362 
Caco-2 cells were treated with an inhibitor of BER pathway, methoxyamine (Mx). Mx 363 
inhibits MPG resulting in AP sites accumulation, a type of lesion that is usually detected 364 
by the comet assay. However, at 72h no increase of DNA damage was detected when 365 
cells were treated with Mx (data not shown), which means that N-alkylations were 366 
repaired thereby not contributing for the increase of DNA damage detected in the 367 
presence of BG. The use of Mx demonstrates that the assay is detecting O
6
meG only. 368 
Further confirmation is provided by the use of a second alkylating drug, MMS, which 369 
although inducing N-alkylations virtually does not produce O
6
meG lesions, and no 370 
damage was detected by our system. Therefore in order to assess by comet assay 371 
(CoMeth) O
6
meG levels and infer about MGMT activity we propose the use of 372 
proliferative and MMR proficient cells, such as Caco-2 cells. The assay include several 373 
steps: First, cells should be pretreated with several concentrations of BG, selecting a 374 
concentration sufficient to inhibit all MGMT protein of the cells. Second, cells should 375 
be exposed to the alkylating agent and DNA damage assessed at least at three different 376 
times, 1, 24 and 72h (these points should be chosen according to the doubling time of 377 
the cells). Third, cells without BG treatment should be included as a control. The initial 378 
DNA damages (if present) are repaired over time and, at 72h, in the absence of 379 
pretreatment with BG, the levels of DNA damage should reach control values. 380 
However, in cells pretreated with BG followed by the alkylating agent an increase of 381 
DNA damage will be observed over time. This increase corresponds to the conversion 382 
of O
6
meG into SB by MMR pathway. The difference between DNA damage in cells 383 
with and without pretreatment with BG, reflect O
6
meG levels induced by the alkylating 384 
agent (Fig. 9). This new application of comet assay allows qualitatively assessment of 385 
O
6
meG levels. However, because inhibition reaction of MGMT by BG is a 386 
stoichiometric reaction (1:1), the molar concentration of BG used to inhibited MGMT 387 
allows to infer the amount of MGMT active present in the cells. New advancements in 388 
the comet assay, such as the one described or the recent  high throughput applications 389 
such as GelBond film [35], specific 96-well plates [36, 37], glass microscope slides 390 
[38][39] and micro cell arrays [40][41] make the comet assay an attractive method for 391 
compound screening. In conclusion, we demonstrate that the comet assay can be used 392 
also to assess alkylating DNA damage, specifically O
6
meG, induced in proliferating and 393 
MMR efficient cells, by the use of a specific inhibitor of MGMT. This new application 394 
(CoMeth) allows the study of new MGMT inhibitors, the test of potential 395 
chemopreventive and chemotherapeutic drugs that act by modulating the activity of 396 
MGMT or O
6
meG levels produced, respectively, as well as drugs that increase 397 
expression by demethylation of silenced MGMT or MMR genes. With this new 398 
application to the study of alkylating agents we expect to contribute to the widespread 399 
use of the comet assay. 400 
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 Figure legends 
 
Figure 1. Cell fate and repair of DNA damage induced by methylating agents involving 
MGMT and MMR pathways. 
Figure 2. DNA damage induced by MNU in the presence and absence of BG in Caco-2 
cells, as assessed by the comet assay. Cells were pre-treated without or with BG 
(100µM) (white and black bars, respectively) for 2h before MNU (500µM) treatment 
during 1, 24, 48 and 72h. Results are expressed as mean ± SEM at least three 
independent experiments. Significant differences (* P<0.05) when compared with cells 
without BG treatment at 72h were determined by t-test.   
Figure 3. Effect of MNU (500µM), BG (100µM) and BG plus MNU on apoptosis 
induction in Caco-2 cells . Apoptosis was measured by the TUNEL assay after 48, 72 
and 96h of incubation with the compounds.  Results are expressed as mean ± SEM at 
least three independent experiments. Significant differences (*** P<0.001) when 
compared with the respective control were determined by t-test.   
Figure 4. Effect of different concentrations of BG (0.05-100µM) on MGMT levels in 
Caco-2 cells after 72h of incubation, assessed by western blot. Actin antibody was used 
as a loading control. Results are expressed as mean ± SEM of at least three independent 
experiments. Significant differences (* P<0.05 and *** P<0.001) when compared with 
the control were determined by One-way ANOVA followed by Newman-Keuls 
Multiple comparison test.   
Figure 5. Effect of MNU (500µM), BG (100µM) and BG plus MNU on MGMT protein 
expression in Caco-2 cells. MGMT protein expression was measured after 24, 48 and 72 
of incubation with the compounds by western blot.  The blot image is representative of 
the effect observed in three independent experiments. 
Figure 6. Effect of different concentrations of BG (0.1-100µM) on MNU-induced 
O
6
meG levels in Caco-2 cells as assessed by the comet assay. Cells were pre-treated 
with BG for 2h followed by MNU (500µM) treatment for 1 (grey bars) or 72h (white 
bars). Results are expressed as mean ± SEM at least three independent experiments. 
Significant differences (*** P<0.001) when compared with the respective control were 
determined by One-way ANOVA followed by Newman-Keuls Multiple comparison 
test. 
Figure 7. Effect of MNU on DNA damage, assessed by the comet assay (A) and on 
apoptosis induction, assessed by TUNEL assay (B) in HCT116 cells, in the presence 
and absence of BG. Cells were pre-treated without or with BG (100µM) (white and 
black bars, respectively) for 2h before MNU (500µM) treatment during 1, 24, 48 and 
72h for comet assay and during 48, 72 and 96h for TUNEL assay. Results are expressed 
as mean ± SEM at least three independent experiments. 
Figure 8. DNA damage induced by MMS in Caco-2 cells in the presence and absence of 
BG, as assessed by the comet assay. Cells were pre-treated with BG (0, 1, 10 and 
100µM) for 2h before MMS (200µM) treatment during 1 and 72h. Results are expressed 
as mean ± SEM at least three independent experiments. 
Figure 9. Detection of O
6
meG DNA damage induced by alkylating agents in MMR 
proficient cells using an inhibitor of MGMT by comet assay. Representation of possible 
results and interpretation.  
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